MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/j.1365-2141.2011.08615.x

Медицинская библиотека · British journal of haematology · 2011

Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.

Shaw Bronwen E, Apperley Jane F, Russell Nigel H, Craddock Charles, Liakopoulou Effie, Potter Michael N, Wynn Robert, Gibson Brenda, Pearce Rachel M, Kirkland Keiren, Lee Julia, Madrigal J Alejandro, Cook Gordon, Byrne Jennifer L

Клиническое исследованиеСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

There is little information published comparing peripheral blood stem cells (PBSC) with bone marrow (BM) as the stem cell source in the long-term outcome in recipients of T-cell depleted (TCD) unrelated donor (UD) transplants. We present retrospective outcome data on 306 recipients of myeloablative, human leucocyte antigen-matched UD allografts using pre-transplant in-vivo Alemtuzumab. Transplants were performed between 2000 and 2007 for chronic myeloid leukaemia in first chronic phase and acute leukaemia in first or second complete remission; 184 patients received BM and 122 PBSC. The median age was 28·9 years (<1-58) and the median follow-up was 48 months. Overall survival at 8 years was 53%. The incidence of acute graft-versus-host disease (GvHD) was significantly higher in PBSC (65%) than BM recipients (49%; P=0·012). This represented only grade 1 GvHD with no difference in grade II-IV aGvHD (BM 23% PBSC 24%). The incidence of chronic GvHD, either overall (BM 47%, PBSC 49%) or extensive (BM 15%, PBSC 13%) was not increased with PBSC. The incidence of relapse, non-relapse mortality and survival were not significantly different. Whilst accepting the limitations of retrospective analyses, we suggest the increased risk of GvHD in recipients of PBSC in T-replete transplants is offset by in-vivo Alemtuzumab, and that either stem cell source can be used with good outcomes in this setting.

Для цитирования: Shaw Bronwen E, Apperley Jane F, Russell Nigel H, Craddock Charles, Liakopoulou Effie, Potter Michael N, Wynn Robert, Gibson Brenda, Pearce Rachel M, Kirkland Keiren, Lee Julia, Madrigal J Alejandro, Cook Gordon, Byrne Jennifer L. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.. British journal of haematology. 2011. DOI: 10.1111/j.1365-2141.2011.08615.x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.